Drug Approval | June 29, 2025
Briefs: Neuland Laboratories and Granules India
Granules India receives 1 observation from USFDA for Chantilly facility
Granules India receives 1 observation from USFDA for Chantilly facility
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Subscribe To Our Newsletter & Stay Updated
